Why a thyroid biopsy does not have one all-inclusive price
A quoted thyroid-biopsy price may cover only tissue sampling, or it may bundle ultrasound guidance and the first pathology reading.
Consultation, guidance ultrasound, cytology or histology, cell-block work, immunostaining, a molecular test such as BRAF, dressings, and medicines can appear as separate lines.
This South Korean calculator does not publish a Korean national-average price.
It compares two itemized provider quotes using the gross covered charge, the billing office’s confirmed patient-share rate, disclosed non-covered amounts, and a payout confirmed by the insurer for the same scope.
Every money field starts at zero because an unknown amount should not be replaced with an invented market estimate.
Sampling procedure
Confirm fine-needle aspiration (FNA) or core-needle biopsy (CNB), the actual procedure name, and the EDI code.
Image guidance
Separate diagnostic ultrasound from same-day biopsy guidance and confirm what is bundled.
Pathology and molecular work
Keep the base reading, additional pathology, and molecular testing in separate budget lines.
Repeats and household cost
Model a repeat scenario and add transport or companion-time cost without predicting medical need.
Match FNA and CNB scope before comparing price
Korea’s national health portal explains that FNA draws cells through a thin needle, while CNB removes a small piece of tissue whose architecture is preserved.
The specimen and pathology workflow can therefore differ.
A Provider A FNA quote and a Provider B CNB quote are not automatically comparable merely because both concern the thyroid.
The clinician decides which test and which nodule require sampling; the calculator makes no biopsy recommendation.
Scope checks for thyroid fine-needle aspiration and core-needle biopsy quotes| Scope | FNA | CNB | Confirm before booking |
|---|
| Specimen | Aspirated cells | Architecture-preserving tissue | Actual procedure and pathology type |
| Nodule count | Enter 0–10 | Enter 0–10 | Scope marker, not a unit-price multiplier |
| Add-on testing | Additional pathology or molecular work may be ordered | Additional pathology or molecular work may be ordered | Test name, specimen, coverage, and consented amount |
| Repeat scenario | 0–2 repeats | 0–2 repeats | Reconfirm the actual repeat scope |
How to interpret each input
Do not mix gross covered charges with patient-paid amounts
Enter the total covered amount before copay in the gross covered charge field, then enter the patient-share rate confirmed for this episode.
If the provider already quoted a patient-paid amount for non-covered sampling, ultrasound, pathology, or medicine, enter that amount directly in its own field and do not apply the percentage again.
Separate base pathology from optional add-ons
Base pathology covers the provider-confirmed first specimen processing and reading.
Cell-block work, immunostaining, or another pathology add-on belongs in the additional-pathology field.
A BRAF or other molecular assay belongs in the molecular field only after its exact name, specimen, purpose, coverage status, and patient amount are confirmed.
Subtract only an insurer-confirmed amount
The Generation 1–5 policy choice is a record for the insurance call, not an automatic payout formula.
Korea’s fifth-generation indemnity insurance launched on May 6, 2026, but that date and generation label still do not determine payment for this episode.
Enter only a per-episode amount the insurer confirmed for the same procedure, EDI code, benefit status, and add-on scope.
The calculator caps that amount at the entered medical cost and does not treat transport or companion time as reimbursable.
Formula and worked comparison
One biopsy episode
Covered patient share = gross covered charge × confirmed copay rate
Base medical cost = covered patient share + procedure + guidance + base pathology + consultation and medicine + other
Add-on budget = additional pathology + molecular testing
Household cost after payout = base medical cost + add-on budget − confirmed payout + transport and companion cost
Repeat-inclusive plan = household cost after payout × total episodes
Provider A has a KRW 180,000 gross covered charge and a 40% confirmed patient-share rate, producing a KRW 72,000 covered patient share.
Adding KRW 30,000 for the sampling procedure, KRW 70,000 for guidance, KRW 60,000 for base pathology, and KRW 18,000 for consultation and medicine gives a KRW 250,000 base medical cost.
KRW 20,000 of additional pathology and KRW 180,000 of molecular testing create a KRW 200,000 add-on budget, so medical cost before insurance is KRW 450,000.
After a KRW 150,000 confirmed payout and KRW 50,000 of transport and companion time, household cost is KRW 350,000 per episode.
Worked Provider A and Provider B thyroid biopsy cost comparison| Measure | Provider A | Provider B |
|---|
| Base medical cost | KRW 250,000 | KRW 350,000 |
| Add-on test budget | KRW 200,000 | KRW 250,000 |
| Medical cost before payout | KRW 450,000 | KRW 600,000 |
| Insurer-confirmed payout | KRW 150,000 | KRW 200,000 |
| Household cost per episode | KRW 350,000 | KRW 440,000 |
| Plan with one repeat | KRW 700,000 | KRW 880,000 |
The repeat plan conservatively repeats the entire entered scope, including add-on tests and the same confirmed payout.
If a real repeat omits molecular testing or uses a different method, obtain a new quote and recalculate.
Step-by-step use
- Enter the clinician-confirmed method and planned nodule count for both providers
- Ask each billing office for benefit status, gross covered charge, the patient-share rate for this episode, and any non-covered procedure amount
- Separate guidance ultrasound, base pathology, additional pathology, molecular testing, consultation, medicine, and other patient-paid items
- Give the insurer the exact procedure, EDI code, benefit status, and add-on scope, then enter only the confirmed per-episode payout
- Add transport and companion time and use repeats only as a household cash-planning scenario
- Complete all six scope checks and compare the difference only when the calculator marks the quotes as aligned
Korea 2026 billing and non-covered checkpoints
What C8591 does and does not mean
HIRA materials list na-859(a)/C8591 as thyroid needle biopsy.
It is a useful item to ask about, but it is not an all-inclusive price for guidance ultrasound, cytology, histology, pathology add-ons, molecular testing, or consultation.
Nodule count is not a simple multiplier
A HIRA billing guide explains that sampling both thyroid lobes did not simply permit 200% of a procedure item that lacks a unilateral designation.
Pathology and current billing scope may still differ, so the calculator records nodule count for like-for-like scope and uses the provider’s actual quote for money.
Do not turn one BRAF case into a universal rule
A HIRA fee-review case states that BRAF testing after FNA for a simple thyroid nodule was non-covered under the criterion applied in that case.
Test method, purpose, and current notices can differ, so the calculator never assigns coverage automatically and instead requires the billing office’s current answer.
Do not pre-apply the thyroid-cancer special-case rate
A suspicious nodule or a molecular-test order does not by itself establish registered thyroid cancer or its special copay treatment.
At the booking stage, use only the patient-share rate confirmed for this person and this episode.
The current National Health Insurance Act Articles 41 and 44 in ID 001971, MST 276651, effective January 2, 2026 establish the benefit and patient-share framework.
Enforcement Decree Article 19 in ID 002813, MST 283469, effective February 19, 2026 points to Annex 2 for patient-share rules.
Medical Care Benefit Rules Articles 5 and 9 in ID 006697, MST 285513, effective April 15, 2026 place detailed criteria in notices and non-covered items in Annex 2.
None creates one universal thyroid-biopsy price or copay.
Medical Service Act Articles 45 and 45-2 in ID 001788, MST 285327, effective April 7, 2026 support non-covered price disclosure and reporting.
Published prices can still describe different bundles, so obtain the provider’s itemized quote and detailed statement.
Practical planning scenarios
Comparing two phone quotes
One provider may bundle sampling and base pathology while another lists them separately.
Decompose each quote into the same fields and finish the scope checks before using the price difference.
Preparing cash before consenting to an add-on
The additional-test subtotal shows the difference between the base episode and confirmed additional pathology or molecular work.
If the order may be decided after the first specimen review, enter the provider’s confirmed upper quote only as a conservative cash scenario.
Testing the effect of one repeat
Adding one repeat displays a conservative plan in which the same scope, payout, transport, and companion cost occur again.
It is not a probability estimate or a medical recommendation.
Tips and limits
- Mark the sampling procedure, EDI code, planned nodule count, and base pathology inclusion on each quote
- Ask whether diagnostic ultrasound and same-day guidance ultrasound are bundled or charged separately
- Record the exact add-on test name, specimen, purpose, benefit status, and consented patient amount
- Give the insurer the detailed procedure rather than asking only about a generic thyroid test
- Do not duplicate a charge in both the gross covered field and an already patient-paid field
- Follow the provider’s safety instructions for pain, bleeding, breathing difficulty, or any other symptom after biopsy
The result does not determine medical necessity, cancer probability, pathology, repeat timing, treatment, Korean NHI coverage, or insurance payment.
Ask the clinician for medical decisions, the provider and HIRA for billing questions, and the insurer for policy treatment.
Frequently asked questions
Does sampling two nodules always cost exactly twice as much?
No. Procedure, guidance, and pathology charges do not necessarily rise in the same ratio. The calculator uses nodule count only to align scope and uses the provider’s actual amounts for the budget.
Can C8591 alone produce the total price?
No. It is a useful thyroid needle-biopsy billing anchor, not an all-inclusive bundle. Guidance, cytology or histology, add-on pathology, molecular testing, consultation, and medicine may be separate.
Is BRAF testing always non-covered in Korea?
This calculator does not make that determination. A HIRA case describes the criterion applied to one simple-nodule scenario. Ask the provider about the exact method, purpose, and current rule for this specimen.
Will selecting an indemnity-policy generation calculate a payout?
No. Generation, product, rider, exclusions, limits, benefit status, and test scope all matter. Enter only a payout the insurer confirmed for this episode.
Does a one-repeat budget mean a repeat is medically necessary?
No. It is only a household cash scenario that repeats the entered scope. A clinician decides whether, when, and how any repeat is performed.
Does a zero result mean the biopsy is free?
No. Zero is the blank planning default. Enter the confirmed procedure, guidance, pathology, add-on, consultation, and insurance amounts before interpreting the result.
Primary sources and update boundary
The last official check was August 20, 2026.
The current statutes were checked directly through the Korean Ministry of Government Legislation OPEN API, and HIRA materials were used for C8591, guidance-ultrasound billing questions, the bilateral sampling example, and the BRAF fee-review example.
Korea Disease Control and Prevention Agency health information was used only to explain FNA and CNB scope, not to recommend a test.
Recheck statutes, notices, procedure codes, pathology and molecular-test criteria, non-covered disclosure, and indemnity policy rules whenever the reference date changes.
Finish booking with a like-for-like quote
Align method, nodule count, ultrasound, pathology, add-ons, and repeat assumptions before entering the actual amounts.
Use the result and warning list as a practical checklist for the provider billing office and insurer.